Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00084071 | Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia | PHASE3 | COMPLETED | 2,136 | — | — | May 1, 2004 | Jul 1, 2008 | Dec 19, 2020 | 150 | United States, Argentina +16 |
| Name | Type | Description |
|---|---|---|
| Tifacogin | DRUG | - |
Inclusion Criteria: * Diagnosis of community-acquired pneumonia supported by additional clinical, radiological, and microbiological evidence * Pneumonia of sufficient severity to require ICU admission and management Exclusion Criteria: * Pregnancy * Weight over 150 kg * Patients at increased risk...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE3 | Tozorakimab |
| GSK plc Sponsored ADR | GSK | 3 | PHASE1 | Pn-MAPS30plus, PCV20 |
| Pfizer Inc. | PFE | 4 | — | Receipt of PCV20 |
| Sanofi SA Sponsored ADR | SNY | 1 | — | Undisclosed |
| Gilead Sciences, Inc. | GILD | 1 | — | Undisclosed |
| Grace Therapeutics, Inc. | GRCE | 1 | NA | Undisclosed |
| Co-Diagnostics, Inc. | CODX | 1 | — | Undisclosed |